Dapagliflozin in Patients With CKD, With and Without HF Dapagliflozin in Patients With CKD, With and Without HF
Heart failure is common in patients with chronic kidney disease. Might the SGLT-2 inhibitor dapagliflozin reduce the risk of kidney failure and cardiovascular death in these patients?JACC: Heart Failure
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Cardiology Journal Article Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Forxiga | Heart | Heart Failure | Intensive Care | Urology & Nephrology